In patients with advanced NSCLC and without any mutation in the EGFR gene, docetaxel provides significantly improved progression-free survival compared to erlotinib, according to a phase III randomized trial.
Patients with EGFR mutation-positive lung cancer had improved progression-free survival and better quality of life with new drug afatinib than with standard chemotherapy, according to results from a large phase III trial.
The use of fluorodeoxyglucose positron emission tomography (FDG-PET), for diagnosing lung cancer may have to be rethought. According to an analysis of data from a national prospective trial, FDG-PET has substantially lower sensitivity and specificity than in previously published studies.
A new analysis of four large European trials of cutaneous melanoma patients showed a substantial survival advantage for women, most likely explained by underlying biologic differences.
The addition of sorafenib to isolated limb infusion therapy with melphalan did not improve responses in a new phase I trial of patients with in-transit extremity melanoma.
Maintenance therapy with bevacizumab following combination therapy with bevacizumab, pemetrexed, and carboplatin could be an effective treatment for patients with advanced, nonsquamous non-small-cell lung cancer (NSCLC), according to a new study.
The American Lung Association recently released new guidelines for lung cancer screening, recommending low-dose computed tomography screening in high-risk smokers.
Though the calcium-dependent chloride channel DOG1 is strongly expressed in gastrointestinal stromal tumors (GIST), a new laboratory study suggests that methods targeting it for therapies in treating these cancers are still a ways off.
Researchers at the Mayo Clinic in Rochester, Minnesota, found an eight-fold increase in melanoma incidence among young women between 1970 and 2009 in an epidemiological study. The increase was not as striking among young men, but there was still a four-fold jump in melanoma cases over those four decades.
The presence of a mutation in the MEK1 gene in melanoma patients does not cause resistance to BRAF inhibitor therapy in patients that also carry a BRAF mutation, according to a new study. Previously, experts believed that resistance to the drugs in BRAF-mutated melanoma patients could likely be blamed on the concurrent mutation in MEK1.